創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性

山西證券

2025/07/17

（以下內容從山西證券《創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性》研報附件原文摘錄）藥物點評：CS2009是基石藥業自研的PD-1/VEGF/CTLA-4三特異性抗體。CS2009具有單價PD-1和CTLA-4結合臂以及雙價VEGFA結合臂，通過阻斷PD-1/CTLA-4、激活T細胞及中和VEGFA，實現...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2552438719"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552438719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552438719?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-17 20:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552438719","market":"hk","top_or_hot":-1,"title":"創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性","media":"山西證券","content":"<div>\n<p>（以下內容從山西證券《創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性》研報附件原文摘錄）藥物點評：CS2009是基石藥業自研的PD-1/VEGF/CTLA-4三特異性抗體。CS2009具有單價PD-1和CTLA-4結合臂以及雙價VEGFA結合臂，通過阻斷PD-1/CTLA-4、激活T細胞及中和VEGFA，實現...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071720063097a9bd16&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">山西證券</strong><span class=\"h-time small\">2025-07-17 20:06</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>（以下內容從山西證券《創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性》研報附件原文摘錄）藥物點評：CS2009是基石藥業自研的PD-1/VEGF/CTLA-4三特異性抗體。CS2009具有單價PD-1和CTLA-4結合臂以及雙價VEGFA結合臂，通過阻斷PD-1/CTLA-4、激活T細胞及中和VEGFA，實現...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071720063097a9bd16&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071720063097a9bd16&s=b\">山西證券</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071720063097a9bd16&s=b","article_id":"2552438719","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071720063097a9bd16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552438719","pubTimestamp":1752753982,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"藥物點評：CS2009是基石藥業自研的PD-1/VEGF/CTLA-4三特異性抗體。CS2009具有單價PD-1和CTLA-4結合臂以及雙價VEGFA結合臂，通過阻斷PD-1/CTLA-4、激活T細胞及中和VEGFA，實現多維度的抗腫瘤效應。PD-1報告基因細胞中，CS2009/VEGFA相較CS2009免疫檢查點活性提高約300倍。PD-1，VEGF和CTLA-4三抗聯用可能產生最大的生存獲益，臨床前數據顯示，CS2009明顯優於PD-1/CTLA-4雙抗、PD-1/VEGF雙抗及抗PD-1/抗CTLA-4聯用的抗腫瘤活性，是潛在的腫瘤免疫基石藥物。低劑量組的「冷腫瘤」及PD-1經治患者已觀察到抗腫瘤活性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","02616":"基石药业-B","06978":"永泰生物-B"},"translate_title":"Innovative drug dynamic update: D-1/VEGF/CTLA-4 tertiary antibody CS2009: dose escalation was well tolerated, and anti-tumor activity was observed in cold tumors and PD-(L) 1-treated patients","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06978":1,"02616":0.9},"content_text":"（以下內容從山西證券《創新藥動態更新：D-1/VEGF/CTLA-4三抗CS2009：劑量爬坡耐受性良好，冷腫瘤及PD-(L)1經治患者中觀察到抗腫瘤活性》研報附件原文摘錄）藥物點評：CS2009是基石藥業自研的PD-1/VEGF/CTLA-4三特異性抗體。CS2009具有單價PD-1和CTLA-4結合臂以及雙價VEGFA結合臂，通過阻斷PD-1/CTLA-4、激活T細胞及中和VEGFA，實現多維度的抗腫瘤效應。CS2009有望替代以PD-(L)1為基礎的療法，在PFS和OS帶來獲益。CS2009臨床試驗包括非小細胞肺癌、肝癌、胃癌、子宮內膜癌、卵巢癌、腎細胞癌、結直腸癌及宮頸癌等。CS2009的I期研究為全球多中心臨床，Ia期臨床數據預計2025年第四季度國際學術會議上公布。Ib期/II期劑量擴展研究/關鍵延展研究預計將於2025年下半年啓動。CS2009藥效學數據優秀，食蟹猴耐受性良好。CS2009同時結合PD-1、CTLA-4時親和力更高，通過結合TME中的PD-1/CTLA-4雙陽性T細胞提升療效。CS2009通過與VEGFA二聚體交聯使PD-1/CTLA-4雙報告基因細胞上的檢查點抑制活性提高約150倍。PD-1報告基因細胞中，CS2009/VEGFA相較CS2009免疫檢查點活性提高約300倍。在激活原代T細胞活性的MLR實驗中，與VEGFA二聚體交聯提高了CS2009的活性。食蟹猴GLP毒性試驗中，CS2009對T細胞的激活呈現劑量依賴性。CS2009表現出優異的耐受性，其最高非嚴重毒性劑量和未見明顯毒性反應劑量為100mg/kg。CS2009臨床前數據優於同類藥物。「PD-1+VEGF」組合對比PD-(L)1單藥已證明顯著改善NSCLC患者的PFS，對於OS特別是PD-L1低表達人羣的OS仍有提升空間。「PD-(L)1+CTLA-4」組合OS和PFS獲益顯著，利於長期OS的提高。PD-1，VEGF和CTLA-4三抗聯用可能產生最大的生存獲益，臨床前數據顯示，CS2009明顯優於PD-1/CTLA-4雙抗、PD-1/VEGF雙抗及抗PD-1/抗CTLA-4聯用的抗腫瘤活性，是潛在的腫瘤免疫基石藥物。CS2009在I/II期臨床耐受性良好，「冷腫瘤」及PD-(L)1經治患者觀察到抗腫瘤活性。CS2009的全球I/II期臨床正在澳大利亞和中國招募患者，預計2025年底前患者數將突破100例。計劃擴展至美國進行II期入組。Ia期劑量遞增研究在多線經治的晚期實體瘤患者中完成四個劑量組。第四劑量水平（20mg/kg，Q3W）未發生劑量限制性毒性。研究正在第五劑量水平（30mg/kg，Q3W）入組，觀測CS2009在潛在II期推薦劑量之上的安全性以及拓寬其安全性邊界；同步持續回填前期劑量組（1至20mg/kg，Q3W）。低劑量組的「冷腫瘤」及PD-(L)1經治患者已觀察到抗腫瘤活性。風險提示：創新藥研發失敗及競爭加劇風險，對外授權不及預期風險，藥企融資不及預期風險，臨床推進速度不及預期風險等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}